# OnCo record igor-puzanov (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/igor-puzanov/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "igor-puzanov" ;
  schema:name "Igor Puzanov"@en ;
  schema:description "Led the first talimogene laherparepvec plus ipilimumab study and co-wrote the immune toxicity management guidelines."@en ;
  schema:url <https://onco.cc/people/igor-puzanov/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://www.roswellpark.org/igor-puzanov>, <https://pubmed.ncbi.nlm.nih.gov/?term=Puzanov%20I%5BAuthor%5D> ;
  schema:jobTitle "Director, Early Phase Clinical Trials Program; Chief, Melanoma Section" ;
  schema:sameAs <https://orcid.org/0000-0002-9803-3497> ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/oncolytic-virus/> ;
  onco:drugs <https://onco.cc/drugs/talimogene-laherparepvec/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:institutions <https://onco.cc/institutions/roswell-park/> ;
  schema:affiliation <https://onco.cc/institutions/roswell-park/> .